What is it about?
Imatinib is a commonly used oral tyrosine kinase inhibitor approved for treatment of chronic myeloid leukemia. Ocular adverse events are known, but optic disk edema is rare and almost always reported to appear in the first months of therapy. We here described the occurrence of optic disk edema after 9 years of imatinib therapy and its complete resolution after imatinib discontinuation, without any ocular specialistic treatment.
Featured Image
Why is it important?
The article reports the unusual setting of an adverse event, helping the clinician to think about it when he may encounter it, and suggests a useful strategy of dealing with it.
Perspectives
I think this case report may help doctors dealing with chronic myeloid leukemia (CML) think quickly of tyrosine kinase inhibitors responsibility when an ocular adverse event appear during CML therapy. They may consider immediate temporarily withdrawal of the TKI, even if the drug has been administered to a patient for a long time without any other adverse event.
Dr Marco Santoro
Universita degli Studi di Palermo
Read the Original
This page is a summary of: Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate, Clinical Case Reports, August 2017, Wiley,
DOI: 10.1002/ccr3.1137.
You can read the full text:
Contributors
The following have contributed to this page
